Median PFS was 115 months ( 95 % CI 107-132 ) in the group assigned to mFOLFOX6 plus bevacizumab and 117 months ( 107-129 ) in the group assigned to SOX plus bevacizumab ( HR 104 , 95 % CI 086-127 ; less than non-inferiority margin of 133 , pnon-inferiority = 0014 ) .